A New Golden Age for Target ID: Accessing the Novel Druggable Space with Discovery Proteomics

Pharmaceutical drug development has traditionally focused on a limited number of well-characterized biological targets, but innovative new drug modalities are now rapidly expanding our ability to target proteins previously considered "undruggable". This is ushering a new era for target identification, opening up new areas of the proteome for therapeutic targeting. In this webinar, we discuss how mass spectrometry-based discovery proteomics enables therapeutic developers to rapidly map this novel druggable space, measuring thousands of proteins and PTMs in the blood and tissue proteome with high analytical specificity. We will share how these analyses can lead developers to the most biologically relevant targets – not just the most popular – for greenfield development opportunities that can pave the way for new therapeutic breakthroughs. Presented by Dr. Mo Jain, Founder and CEO of Sapient and Dr. Jonathan Usuka, Chief Business Officer of Sapient Hosted by Oxford Global